key: cord-0794266-nc0bsilq
authors: Dinnon, Kenneth H.; Leist, Sarah R.; Schäfer, Alexandra; Edwards, Caitlin E.; Martinez, David R.; Montgomery, Stephanie A.; West, Ande; Yount, Boyd L.; Hou, Yixuan J.; Adams, Lily E.; Gully, Kendra L.; Brown, Ariane J.; Huang, Emily; Bryant, Matthew D.; Choong, Ingrid C.; Glenn, Jeffrey S.; Gralinski, Lisa E.; Sheahan, Timothy P.; Baric, Ralph S.
title: A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures
date: 2020-05-07
journal: bioRxiv
DOI: 10.1101/2020.05.06.081497
sha: f7f1f34d8eaa98af30392c4a343ca31955645fa3
doc_id: 794266
cord_uid: nc0bsilq

Coronaviruses are prone to emergence into new host species most recently evidenced by SARS-CoV-2, the causative agent of the COVID-19 pandemic. Small animal models that recapitulate SARS-CoV-2 disease are desperately needed to rapidly evaluate medical countermeasures (MCMs). SARS-CoV-2 cannot infect wildtype laboratory mice due to inefficient interactions between the viral spike (S) protein and the murine ortholog of the human receptor, ACE2. We used reverse genetics to remodel the S and mACE2 binding interface resulting in a recombinant virus (SARS-CoV-2 MA) that could utilize mACE2 for entry. SARS-CoV-2 MA replicated in both the upper and lower airways of both young adult and aged BALB/c mice. Importantly, disease was more severe in aged mice, and showed more clinically relevant phenotypes than those seen in hACE2 transgenic mice. We then demonstrated the utility of this model through vaccine challenge studies in immune competent mice with native expression of mACE2. Lastly, we show that clinical candidate interferon (IFN) lambda-1a can potently inhibit SARS-CoV-2 replication in primary human airway epithelial cells in vitro, and both prophylactic and therapeutic administration diminished replication in mice. Our mouse-adapted SARS-CoV-2 model demonstrates age-related disease pathogenesis and supports the clinical use of IFN lambda-1a treatment in human COVID-19 infections.

provide key insights into the pathogenic mechanisms of CoV disease but can serve as highthroughput preclinical evaluation platforms to identify high performance antivirals and vaccines essential for downstream human trials 2,3 . SARS-CoV-2 enters host cells through the binding of the cellular receptor angiotensin-converting enzyme 2 (ACE2). Unfortunately, standard laboratory mice do not support infection with SARS-CoV-2 due to incompatibility of the S protein to the murine ortholog (mACE2) of the human receptor, complicating model development 4 .

Animal models are critical for development of MCMs to combat the COVID-19 pandemic.

While laboratory mice infected with mouse adapted strains of SARS-CoV-1 and MERS CoV have informed our understanding of viral pathogenesis and intervention strategies, the murine ortholog of the human SARS-CoV-2 receptor, mACE2, does not facilitate infection. To determine the utility of hACE2 transgenic mice as a model for SARS-CoV-2 disease, we infected epithelial cell-specific HFH4 promoter driven hACE2-overexpressing mice with SARS-CoV-2 5 . hACE2 mice lost minimal weight yet only 60% survived by 5 days post infection (dpi) (Fig. S1A-B) . Virus replication was observed in the lung but not in the (Fig. S1C ). Similar to previously reported SARS-CoV-1 infection of hACE2 mice, SARS-CoV-2 replication was detected in the brains of those that succumbed to infection suggesting that mortality was driven by viral neuroinvasion (Fig. S1 D) .

Lastly, whole body plethysmography (WBP) reveals pulmonary function remained at normal levels for the duration of these studies proving further evidence that respiratory infection was likely not a major driver of mortality ( Fig. S1F-G) . Thus, in the presence of a hACE2 transgene, mice fully support SARS-CoV-2 replication but the observed pathogenesis failed to accurately model the disease course seen in humans.

Rather than alter the host, we next sought to remodel the SARS-CoV-2 spike receptor binding domain to facilitate efficient binding to mACE2 and therefore productive viral infection.

Upon comparing the ACE2 contact residues in the RBDs of several group 2B coronaviruses capable of infecting mice (i.e. SARS-CoV-1, WIV1, and SHC014) to those of SARS-CoV-2, residue 498 of SARS-CoV-2 was uniquely divergent (Fig. 1A, Fig. S2 ). In addition, molecular modeling of the SARS-CoV-2 RBD and receptor interface revealed a loss of interaction between Q498 of the SARS-CoV-2 spike and Q42 of mACE2 (Fig 1B-C) , which may diminish binding efficiency. Thus, we predicted the substitution of residue Q498, and adjacent P499, with those from WIV1 and SARS-CoV-1 would restore the interaction with Q42 of mACE2, while preserving interaction with hACE2 ( Fig. 1D-E) . Using reverse genetics, we engineered Q498T/P499Y into the SARS-CoV-2 S gene and recovered the recombinant virus (SARS-CoV-2 MA). Importantly, SARS-CoV-2 MA replicated to similar levels as the parental WT virus in Vero E6 cells (Fig. 1F ) and unlike WT virus, SARS-CoV-2 MA could infect cells expressing mACE2 (Fig. 1G ).

After demonstrating SARS-CoV-2 MA could utilize mACE2 for entry, we sought to determine if this virus could infect young adult WT mice. While overt clinical signs of infection (i.e. weight loss) were not observed in young adult BALB/c mice infected with 10 5 PFU SARS-CoV-2 MA ( Fig. 2A) , high titer virus replication (6.93x10 5 PFU/tissue) was noted in lung tissue on 2dpi but was cleared by 4dpi (Fig. 2B) . Under identical conditions, SARS-CoV-2 did not replicate in mice. Histological analysis of SARS-CoV-2 MA infected mice revealed inflammation of small conducting airways on 2dpi, associated with high levels of viral antigen staining (Fig. S3A ). Viral replication was limited to conducting airways and absent in interstitium, and is absent on 4dpi, concordant with clearance of viral titer (Fig. 2B, Fig. S3B ). Similar to that observed in humans, SARS-CoV-2 MA replication was also observed in the upper airway although the magnitude was less than that seen in the lung (Fig. 2C ). The loss of pulmonary function as measured by WBP is commonly observed in murine models of emerging CoV pathogenesis 6, 7 and is an important clinically relevant measure of disease. Using WBP, we evaluated several complementary metrics of pulmonary obstruction and bronchoconstriction including PenH and Rpef. Interestingly, SARS-CoV-2 MA young infected mice showed a small but significant change in PenH (Fig. 2D ) and a significant decrease in Rpef (Fig. 2E ) on 2dpi indicative of a decrease in lung function. Thus, like often seen in young adult humans, infection of young adult mice with SARS-CoV-2 MA resulted in efficient virus replication in the upper and lower airways, limited replication in the parenchyma and was associated with mild to moderate disease.

Higher morbidity and mortality rates have been consistently observed in older human populations throughout the COVID-19 pandemic 8 . Additionally, wildtype and mouse adapted SARS-CoV-1 shows strong age dependent disease phenotypes in humans and mice, respectively 9, 10 . To determine if the age-related increase in pathogenesis observed in SARS-CoV-2 infected humans would translate to infection of aged mice, we infected 12-month-old BALB/c mice with SARS-CoV-2 MA. In contrast to young adult mice, aged BALB/c mice exhibited a transient yet significant decrease in body weight by 3dpi, which was recovered by 4dpi (Fig. 3A ).

Old mice also had high titers at 2dpi (1.07x10 6 PFU/tissue) and detectable virus titers at 4dpi.

Similarly, replication in the upper airway persisted in half of the mice at 4dpi (Fig. 3C ). Compared to young mice, SARS-CoV-2 MA infected old mice displayed increased inflammation in the lung at 2dpi and 4dpi, and viral antigen was found in both conducting airway epithelium and interstitium (Fig S4A-B) . Additionally, at 4dpi, SARS-CoV-2 MA infection induced hemorrhage and formation of bronchus-associated lymphoid tissue (BALT) (Fig. S4B) . Lastly, the loss of pulmonary function was more pronounced in aged animals as evidenced by significant differences in PenH and Rpef among mock and SARS-CoV-2 MA infected animals ( Fig. 3D -E).

As demonstrated with mouse adapted strains of SARS-CoV-1 11-15 , a replication competent SARS-CoV-2 MA strain promotes in vivo pathogenesis studies, and importantly, allows for rapid testing of intervention strategies in standard laboratory mice during an expanding pandemic.

Utilizing a Venezuelan equine encephalitis virus replicon particle (VRP) system, we vaccinated 10-

week-old BALB/c mice against SARS-CoV-2 spike (S), nucleocapsid (N), and GFP as a control, Interferon lambda is a type III interferon whose receptors are largely limited to epithelial cells, including the lungs, liver, and gastrointestinal tract 16, 17 lowered nasal turbinate titer compared to vehicle treated mice, though not statistically significant due likely due to the limit of detection (Fig. 4F ). Altogether, these data demonstrate the utility of this model to rapidly evaluate vaccine and therapeutic drug efficacy in standard laboratory mice. In addition, we show that peg-IFN-l1 exerts potent antiviral activity against SARS-CoV-2 in vitro and can diminish virus replication in vivo even when given therapeutically.

Structural studies have solved the interactive networks associated with the SARS-CoV and SARS-CoV-2 RBD interaction residues that bind hACE2 19, 20 . Coupling predictive molecular modeling and reverse genetics 21 Although the SARS-CoV-2 MA RBD mutations may attenuate the function of select human monoclonal antibodies or vaccines in mice, this phenotype was not observed with mouse adapted strains of SARS-CoV-1 [29] [30] [31] . In any event, we demonstrate that our previously described hACE2 transgenic mouse model supports efficient SARS-CoV-2 replication and pathogenesis in vivo, as well 5 . Consequently, this model offers an alternative replication and disease model that uses wildtype SARS-CoV-2, appropriate for evaluating therapeutic antibodies that bind the RBD and other countermeasures. In comparison to SARS-CoV-1 infection, SARS-CoV-2 infection results in a mild bronchiolitis in young mice characterized by efficient virus growth, minimal weight loss and about 40% mortality, the latter phenotype associated with viral invasion of the CNS. In hACE2 transgenic mice, neuroinvasion is a common pathologic outcome following SARS-CoV infection and a major driver of mortality 5, 32 . Together, these data describe critical new animal models, demonstrate countermeasure potential and provide key recombinant viruses for further mouse adaptation, leading to 2 nd generation mouse models of human disease.

Group 2B coronavirus spike and ACE2 amino acid sequences were aligned using Geneious (NP_081562). Protein similarity scores were calculated using BLOSUM62 matrix. Contact residues previously identified by crystal structures 19, 20, 33 . Structure modelling was performed using Modeller (Version 9.20) and visualized using PyMOL (Version 1.8.6.0).

All viruses used were derived from an infectious clone of SARS-CoV-2, which was designed using similar strategies for SARS-CoV and MERS-CoV (14569023, 24043791). The Q498Y/P499T substitutions were generated by site directed mutagenesis using the following primers: Forward: Vero E6 cells were maintained in n Dulbecco's modified Eagle's medium (DMEM; Gibco), 5% Fetal Clone II serum (FCII, Hyclone), and 1X antibiotic/antimycotic (Gibco). DBT-9 were maintained in DMEM, 10% FCII, and 1X antibiotic/antimycotic. For single step growth curve, Vero E6 cells were infected at a multiplicity of infection (MOI) of 1 for 1 hour. Inoculum was removed and monolayer was washed twice with PBS, and replace with media. At designated timepoints, media was removed without replacement, and stored at -80°C until titered by plaque assay as described above.

For ACE2 receptor usage, non-permissive DBT-9 cells were transfected with pcDNA3. HAEs were treated with a range of peg-IFN-l1 doses basolaterally for 24hrs prior to infection.

1µM remdesivir was obtained from Gilead Sciences by MTA and was used as a positive control.

Cultures were infected at an MOI of 0.5 for 2 hours. Inoculum was removed and culture was washed three times with PBS. At 48hrs post infection, apical washes were taken to measure viral replication via plaque assays as described above. This study was repeated in two separate human donors.

Mice were subcutaneously treated with a single 2µg dose of peg-IFN-l1 prophylactically at 18hrs prior to infection, therapeutically at 12hrs post infection, or PBS vehicle treated, and infected with 10 5 plaque forming units (PFU) of SARS-CoV-2 MA intranasally under ketamine/xylazine anesthesia. Body weight was monitored daily. On day 2 post infection, mice were euthanized by isoflurane overdose and tissue samples were harvested for titer analysis as described above.

Lungs were fixed for 7 days in 10% phosphate buffered formalin, paraffin embedded, and sectioned at 4µm. Serial sections were stained with hematoxylin and eosin, and stained for immunohistochemistry for SARS-CoV-2 nucleocapsid using a monoclonal anti-SARS-CoV-1 nucleocapsid antibody (NB100-56576, Novus Biologicals) on deparaffinized sections on the Ventana Discovery Ultra platform (Roche). Photomicrographs were captured on an Olympus BX43 light microscope at 200X magnification with a DP27 camera using cellSens Dimension software.

All data visualize and analyzed in Prism (version 8.4.2). Non-parametric tests were 

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-like WIV1-CoV poised for human emergence

New Metrics for Evaluating Viral Respiratory Pathogenesis

A mouse model for MERS coronavirus-induced acute respiratory distress syndrome

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

SARS and MERS: recent insights into emerging coronaviruses

Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans

Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus

A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge

MyD88 is required for protection from lethal infection with a mouseadapted SARS-CoV

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

IL-28, IL-29 and their class II cytokine receptor IL-28R

Emerging concepts for the treatment of hepatitis delta

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

Comparison between umbilical artery and vein endogenous digoxin-like immuno-active factor levels in normal and preeclamptic patients

Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease

A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)

COVID-19: lambda interferon against viral load and hyperinflammation

IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections

Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus

Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness

Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Structure of SARS coronavirus spike receptorbinding domain complexed with receptor

Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform

Supplemental Figure 1: SARS-CoV-2 infection in hACE2 transgenic mice. (A) Percent starting weight. Percent starting weight. Dotted line represents weight loss criteria for humane euthanasia. Data analyzed by mixed effects analysis followed by Sidak's multiple comparisons. (B) Survival. (C) Lung viral titer. (D) Brain viral titer

Undetected samples are plotted at half the limit of detection. 'x' symbol indicates mice that succumbed to infection. (E-F) Whole body plethysmography assessing pulmonary function for

Data analyzed by mixed effects analysis followed by Sidak's multiple comparisons. The line represents the mean and error bars represent standard error of the mean

Supplemental Figure 2: Group 2B coronavirus spike receptor binding domain alignment

Supplemental Figure 3: Histology and SARS-CoV-2 MA antigen staining in young BALB/c lungs

Representative images of lung sections from 12-week-old BALB/c mice from Fig. 2. (A) 2dpi. (B) 4dpi. Top panels are hematoxylin and eosin (H & E). Bottom panels are immunohistochemistry staining for SARS-CoV-2 nucleocapsid protein

Supplemental Figure 4: Histology and SARS-CoV-2 MA antigen staining in old BALB/c lungs

Representative images of lung sections from 1-year-old BALB/c mice from Fig. 2. (A) 2dpi. (B) 4dpi. Top panels are hematoxylin and eosin (H & E). Bottom panels are immunohistochemistry staining for SARS-CoV-2 nucleocapsid protein